ArticleEuropean journal of haematology2017
Inpatient vs outpatient autologous hematopoietic stem cell transplantation for multiple myeloma.
Article in European journal of haematology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Ambulatory models for autologous stem-cell transplantation: a systematic review of the health impact.Frontiers in immunology · 2024Pooled it
- Pooled it
- Pooled it
- Efficacy and safety of air-flow beds for autologous hematopoietic stem cell transplantation in multiple myeloma: a retrospective cohort study.Frontiers in oncology · 2026Article
- Contextual analysis of hematopoietic stem cell transplantation in outpatients.Revista brasileira de enfermagem · 2026Article
- Comparable peri-transplant mortality and incidence of febrile neutropenia after high-dose melphalan and autologous stem cell transplantation in patients with plasma cell dyscrasias treated as outpatient versus inpatient.British journal of haematology · 2025Article
- Autologous stem cell transplantation for multiple myeloma patients whose myeloma-defining event was SLiM.British journal of haematology · 2025Article
- High Serum miR-361-3p Predicts Early Postdischarge Infections after Autologous Stem Cell Transplantation.Infection & chemotherapy · 2024Article
- MicroRNAs predict early complications of autologous hematopoietic stem cell transplantation.Biomarker research · 2024Article
- Serum Levels of miR-122-5p and miR-125a-5p Predict Hepatotoxicity Occurrence in Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation.International journal of molecular sciences · 2024Article
- Multiple Myeloma: Current Clinical Landscape and Compounding Costs.Current hematologic malignancy reports · 2023Review
- Home-Based Hematopoietic Cell Transplantation in the United States.Transplantation and cellular therapy · 2022Article
- Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission.Journal of clinical medicine · 2022Article
- Implementation of a hospital-at-home (HAH) unit for hematological patients during the COVID-19 pandemic: safety and feasibility.International journal of hematology · 2022Article
- Autologous stem cell transplantation for multiple myeloma patients aged ≥ 75 treated with novel agents.Bone marrow transplantation · 2021Article
- Cardiovascular risk assessment and management of patients undergoing hematopoietic cell transplantation.Bone marrow transplantation · 2021Review
- DCEP and bendamustine/prednisone as salvage therapy for quad- and penta-refractory multiple myeloma.Annals of hematology · 2020Article
- Multiple Myeloma Outpatient Transplant Program in the Era of Novel Agents: State-of-the-Art.Frontiers in oncology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundHigh-dose chemotherapy and autologous hematopoietic stem cell transplantation (auto-HCT) are commonly performed for multiple myeloma (MM) patients and may be as safe in the outpatient setting as in the inpatient setting.
methodsWe performed a single-center retrospective analysis of all MM patients undergoing auto-HCT between January 2008 and December 2012. We categorized patients as outpatient vs inpatient auto-HCT and compared clinical characteristics and outcomes between the groups.
resultsOne thousand and forty-six patients were included (669 inpatients, 377 outpatients). Patients transplanted as outpatients were significantly younger (58 [34-78] vs 62 [31-82], P < .001) and more likely to have an hematopoietic stem cell comorbidity index (HCT-CI) score <2 (P = .003) and creatinine <2 (P < .001). There were no differences in treatment-related mortality (TRM) but the inpatient group experienced significantly more grade 2-5 (P = .003) and grade 3-5 (P = .003) adverse events (AEs). 2 year progression-free survival (PFS) was significantly longer in the outpatient group (60% vs 50%, HR =HR 0.7, 95% CI 0.6-0.9, P = .005). 2 year OS was also longer in the outpatient group (83% vs 77%, HR 0.6, 95% CI 04-0.9, P = .01).
conclusionOutpatient auto-HCT can be safely performed for selected patients with MM. Differences in outcomes are likely related to baseline clinical characteristics rather than choice of treatment setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.